Lenalidomid Sun (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, changing the complex’s substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to reduced tumor cell proliferation, increased apoptosis, enhanced immune cell activity, and inhibition of new blood‑vessel formation that supports cancer growth.

The dosing regimen for Lenalidomid Sun is individualized and must be determined by a qualified prescriber based on the specific indication, disease status, renal function, and other patient‑specific factors. Healthcare professionals follow approved labeling and clinical guidelines to set the appropriate dose and schedule.

Lenalidomid Sun is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lenalidomid Sun. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class, which also includes thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally has a more favorable safety profile, especially regarding peripheral neuropathy, and offers stronger anti‑angiogenic and immune‑activating effects. Pomalidomide is a newer IMiD with activity in patients who have progressed after lenalidomide, but it may carry a higher risk of hematologic toxicity.

Lenalidomid Sun tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original blister pack or container, protect it from moisture, excessive heat and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Lenalidomid Sun is administered orally as a tablet. Patients should swallow the tablet whole with a glass of water, preferably on an empty stomach unless directed otherwise by the prescriber. The exact timing relative to meals and any required dose adjustments are determined by the treating physician.

The most serious adverse events include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to serious infections, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Regular monitoring of blood counts, liver function and vigilance for signs of clotting or infection are essential.

Lenalidomid Sun should not be used by pregnant women or women who could become pregnant without effective contraception. Patients with uncontrolled severe renal impairment, active uncontrolled infections, or a history of severe hypersensitivity to lenalidomide or any component of the formulation should avoid the drug. The prescriber must evaluate each individual’s risk before initiating therapy.